A 2020 update on liver transplant for hepatocellular carcinoma

被引:16
|
作者
Finotti, Michele [1 ]
Vitale, Alessandro [1 ]
Volk, Michael [2 ]
Cillo, Umberto [1 ]
机构
[1] Padova Univ Hosp, Dept Surg Oncol & Gastroenterol, Hepatobiliary Surg & Liver Transplantat Unit, Padua, Italy
[2] Loma Linda Univ Hlth, Div Gastroenterol & Hepatol, Loma Linda, CA USA
关键词
Benefit Models; downstaging; hepatocellular Carcinoma; liver transplantation; primary Liver Transplant; salvage Liver Transplant; transplant benefit; TO-LYMPHOCYTE RATIO; ALPHA-FETOPROTEIN; MICROVASCULAR INVASION; SURVIVAL BENEFIT; WAITING-LIST; TRANSARTERIAL CHEMOEMBOLIZATION; SALVAGE TRANSPLANTATION; LOCOREGIONAL THERAPY; SELECTION CRITERIA; MILAN CRITERIA;
D O I
10.1080/17474124.2020.1791704
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction Hepatocellular carcinoma is the most frequent liver tumor and is associated with chronic liver disease in 90% of cases. In selected cases, liver transplantation represents an effective therapy with excellent overall survival. Area covered Since the introduction of Milan criteria in 1996, numerous alternative selection systems to LT for HCC patients have been proposed. Debate remains about how best to select HCC patients for transplant and how to prioritize them on the waiting list. Expert opinion The selection of the best scoring system to propose in the context of LT for HCC is far to be identified. In this review, we analyze and categorize the various selection systems, assessing their roles in the different decisional phases.
引用
收藏
页码:885 / 900
页数:16
相关论文
共 50 条
  • [21] Changing opportunities for liver transplant for patients with hepatocellular carcinoma
    Zendel, Alex
    Watkins, Randall
    Moon, Andrew M.
    Gerber, David A.
    Barritt, A. Sidney
    Desai, Chirag S.
    CLINICAL TRANSPLANTATION, 2022, 36 (05)
  • [22] New Developments in Orthotopic Liver Transplant for Hepatocellular Carcinoma
    Marino, Ignazio R.
    Carr, Brian I.
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2017, 15 : 1 - 6
  • [23] Sociodemographic disparities in downstaging to liver transplant for hepatocellular carcinoma
    Zhou, Kali
    Nguyen, Lauren
    Tabrizian, Parissa
    Mehta, Neil
    LIVER TRANSPLANTATION, 2024,
  • [24] Spontaneous rupture of a hepatocellular carcinoma: is a liver transplant indicated?
    Prieto-Puga Arjona, Tatiana
    Romacho Lopez, Laura
    Suarez Munoz, Miguel Angel
    Sanchez Perez, Belinda
    Santoyo Santoyo, Julio
    CIRUGIA ESPANOLA, 2015, 93 (07): : 478 - 479
  • [25] Sorafenib for Hepatocellular Carcinoma Recurrence After Liver Transplant
    Mancuso, Andrea
    TRANSPLANTATION, 2020, 104 (08) : E243 - E243
  • [26] Use of Metformin in Liver Transplant Recipient With Hepatocellular Carcinoma
    Choi, J.
    Lee, K.
    Rhu, J.
    Gil, E.
    Na, B.
    Oh, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 750 - 750
  • [27] Management of recurrent hepatocellular carcinoma after liver transplant
    Chok, Kenneth S. H.
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (08) : 1142 - 1148
  • [29] Liver transplantation for hepatocellular carcinoma: Management after the transplant
    Verna, Elizabeth C.
    Patel, Yuval A.
    Aggarwal, Avin
    Desai, Archita P.
    Frenette, Catherine
    Pillai, Anjana A.
    Salgia, Reena
    Seetharam, Anil
    Sharma, Pratima
    Sherman, Courtney
    Tsoulfas, Georgios
    Yao, Francis Y.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (02) : 333 - 347
  • [30] A New Liver Transplant Priority for Patients with Hepatocellular Carcinoma
    Ravaioli, Matteo
    Grazi, Gian Luca
    Vetrone, Gaetano
    Kimura, Takuya
    Zanello, Matteo
    Ercolani, Giorgio
    Cescon, Matteo
    Varotti, Giovanni
    Del Gaudio, Massimo
    Tuci, Francesco
    Cucchetti, Alessandro
    La Barba, Giuliano
    Vivarelli, Marco
    Lauro, Augusto
    Ramacciato, Giovanni
    Pinna, Antonio Daniele
    HEPATO-GASTROENTEROLOGY, 2008, 55 (86-87) : 1742 - 1745